Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) Equity Average (2020 - 2025)

Treace Medical Concepts' Equity Average history spans 6 years, with the latest figure at $88.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 18.95% year-over-year to $88.3 million; the TTM value through Dec 2025 reached $88.3 million, down 18.95%, while the annual FY2025 figure was $100.1 million, 20.18% down from the prior year.
  • Equity Average reached $88.3 million in Q4 2025 per TMCI's latest filing, down from $93.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $153.8 million in Q2 2023 to a low of $46000.0 in Q1 2021.
  • Average Equity Average over 5 years is $97.5 million, with a median of $100.8 million recorded in 2021.
  • The largest YoY upside for Equity Average was 195433.7% in 2022 against a maximum downside of 35.56% in 2022.
  • A 5-year view of Equity Average shows it stood at $95.2 million in 2021, then plummeted by 35.56% to $61.4 million in 2022, then soared by 124.72% to $137.9 million in 2023, then fell by 21.03% to $108.9 million in 2024, then fell by 18.95% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Equity Average are $88.3 million (Q4 2025), $93.4 million (Q3 2025), and $101.5 million (Q2 2025).